Dr. Sherman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-7296- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1991
- Johns Hopkins UniversityResidency, Internal Medicine, 1986 - 1988
- Johns Hopkins UniversityInternship, Internal Medicine, 1985 - 1986
- Johns Hopkins University School of MedicineClass of 1985
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 1985 - Present
- WA State Medical License 2023 - 2026
- TN State Medical License 2023 - 2025
- AZ State Medical License 2023 - 2025
- OK State Medical License 2020 - 2025
- TX State Medical License 1994 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Start of enrollment: 2004 Dec 01
- Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer Start of enrollment: 2001 Mar 01
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Start of enrollment: 2008 Jun 01
Publications & Presentations
PubMed
- Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.Gouda, M., Iorgulescu, J., Shen, T., Wu, J., Subbiah, V., Dadu, R., Patel, K., Sherman, S., Cabanillas, M., Hu, M., Castellanos, L., Amini, B., Meric-Bernstam, F.> ;NPJ Precision Oncology. 2024 Mar 4
- Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascul...Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W...> ;Thyroid. 2024 Mar 1
- 9 citationsCabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.Marcia S Brose, Bruce G Robinson, Steven I Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W Bowles, Suvajit Sen, Jennifer W O...> ;Cancer. 2022 Dec 15
- Join now to see all
Journal Articles
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineThinh Vu, Naifa L Busaidy, Maria E Cabanillas, Steven G Waguespack, Steven I Sherman, Mark Zafereo, The Journal of Clinical Endocrinology and Metabolism
Lectures
- New Medical Options for the Treatment of Advanced Thyroid CancerENDO 2019 - New Orleans, LA - 3/24/2019
Other
- Chemotherapy and immunotherapy for medullary thyroid cancerSherman SI
http://www.uptodate.com/contents/chemotherapy-and-immunotherapy-for-medullary-thyroid-cancer
UpToDate, Wolters Kluwer Health - 2013-02-21 - Chemotherapy for differentiated thyroid cancerSherman SI
http://www.uptodate.com/contents/chemotherapy-for-differentiated-thyroid-cancer
UpToDate, Wolters Kluwer Health - 2013-02-25
Press Mentions
- Cabozantinib Improved Survival in Medullary Thyroid Cancer with RET MutationsOctober 23rd, 2015
Professional Memberships
- Member
- Member
- Member
- Member
- International Thyroid Oncology GroupMember
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: